Results 81 to 90 of about 498,238 (269)
A macrophage–platelet conjugation system (M‐P‐NPs@PPARγ) targets injure tissue to co‐deliver platelet mitochondria and PPARγ‐encoding NPs. This strategy boosts the macrophage energy supply and restores lipid homeostasis, leading to synergistically enhanced efferocytosis and tissue repair Abstract Mitochondrial dysfunction occurs in macrophages with ...
Haoli Wang +18 more
wiley +1 more source
A microfluidic electrochemical biosensor enables sensitive and specific detection of antibodies associated with vaccine‐induced immune thrombotic thrombocytopenia (VITT) and heparin‐induced thrombocytopenia (HIT). The platform uses two antigen targets— platelet factor 4 (PF4) and cross‐linked‐PF4 (c‐PF4)—and microliter volumes of patient sera to ...
Diana F. Cedillo‐Alcantar +8 more
wiley +1 more source
Combined Use of Tranexamic Acid and Rivaroxaban in Posterior/Transforaminal Lumbar Interbody Fusion Surgeries Safely Reduces Blood Loss and Incidence of Thrombosis: Evidence From a Prospective, Randomized, Double-Blind, Placebo-Controlled Study [PDF]
Xiang Li +6 more
openalex +1 more source
This study develops a biomimetic nanoplatform using erythrocyte membrane‐camouflaged, CD144 antibody‐functionalized nanoparticles to deliver 2‐deoxy‐D‐ribose (2dDR). This system promotes heart valve endothelialization by enhancing endothelial cell migration and proliferation via EGFR activation, while improving hemocompatibility.
Xiang Qiu +11 more
wiley +1 more source
Targeting DESI2 as a Novel Therapeutic Strategy for JAK2‐Mutant Leukemias
Mass spectrometry‐based proteomics identify DESI2 as a novel component of the JAK2‐V617F complex, which associates with and stabilizes mutant JAK2 through deSUMOylation and deubiquitination, therefore promoting JAK2 mutant cell growth and MPN disease onset in vivo.
Husheng Mei +32 more
wiley +1 more source
Targeting DNA‐LNPs to Endothelial Cells Improves Expression Magnitude, Duration, and Specificity
Attaching antibodies against endothelial cell surface proteins redirects the delivery and expression of DNA‐lipid nanoparticles to organs of interest. Our targeted nanoparticles enable organ‐selective DNA expression in the endothelium of the lungs, brain, or spleen, providing a therapeutic platform for dozens of endothelial‐centric diseases.
Nicolas Marzolini +24 more
wiley +1 more source
Primary Myelofibrosis in the Prefibrotic Stage Presenting as Portal, Splenic, and Superior Mesenteric Vein Thrombosis: A Case Report and Review of the Literature [PDF]
Emanuel Dias +5 more
openalex +1 more source

